News Snapshot:
Beijing: A vaccine developed by Sichuan Clover Biopharmaceuticals Inc. was found to prevent 79% of Covid-19 cases of any severity caused by the Delta variant in late-stage trials, making it the first Chinese shot to offer clear efficacy data against the variant causing resurgent waves of infections around the world. The Clover candidate deploys protein on the coronavirus to stimulate immunity against COVID-19, an approach also used by the inoculation developed by Novavax Inc. It is 100% effective against severe COVID-19 caused by any variants detected in the trial, including Delta, Gamma and Mu, which first emerged from India, Brazil...
